Eliana Clark is CTO & VP at Intellia Therapeutics, Inc. (NTLA). They have made 10 open-market trades across 1 company since 2022, most recently 2026-03-02.
CIK 0001914448
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 93,864 | $1.2M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2026-03-02 | 2026-03-03 | $13.78 | $8K | -8.7% | -6.1% | -1.9% |
| NTLA | SELL | 2026-01-05 | 2026-01-07 | $9.21 | $88K | +19.7% | +14.6% | +26.5% |
| NTLA | SELL | 2025-07-01 | 2025-07-03 | $9.82 | $10K | +12.3% | +13.8% | +76.2% |
| NTLA | SELL | 2025-03-04 | 2025-03-04 | $8.99 | $6K | -2.8% | -26.7% | -23.8% |
| NTLA | SELL | 2025-01-02 | 2025-01-06 | $12.17 | $187K | -25.8% | -17.9% | -48.9% |
| NTLA | SELL | 2024-07-01 | 2024-07-03 | $22.93 | $9K | +20.0% | +4.6% | -15.8% |
| NTLA | SELL | 2024-03-04 | 2024-03-05 | $32.99 | $20K | -8.2% | -19.0% | -23.7% |
| NTLA | SELL | 2024-01-03 | 2024-01-05 | $29.48 | $263K | -10.4% | -11.9% | -11.4% |
| NTLA | SELL | 2023-07-03 | 2023-07-06 | $40.51 | $15K | +12.4% | -0.7% | -26.4% |
| NTLA | SELL · 10b5-1 | 2023-06-20 | 2023-06-22 | $45.00 | $225K | -1.6% | +2.0% | -17.3% |
| NTLA | SELL | 2022-07-01 | 2023-01-06 | $37.45 | $139K | -13.2% | +14.3% | -6.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.